Company
- Home
- About Company
Founder
Celestin Missikpode ,MD,PHD
Founder, BioTraject Systems
Dr. Celestin Missikpode is the founder of BioTraject Systems, a computational medicine company developing products for chronic disease modeling, forecasting, and decision support. The company was founded on the conviction that many chronic diseases are too dynamic, heterogeneous, and longitudinally complex to be fully understood through static scores, isolated thresholds, or one-time predictions alone. Grounded in scientific rigor, patient-specific modeling, and real-world healthcare complexity, BioTraject Systems aims to build tools that make disease progression easier to see, interpret, and act on over time. Its products are designed to help clinicians and health systems understand disease trajectories, evaluate intervention strategies, and support more informed decisions. NephroSync™, the company’s first flagship product in development, reflects this vision in chronic kidney disease.
Background And Expertise
Dr. Celestin Missikpode is a physician-scientist whose work bridges clinical medicine, public health, machine learning, and systems thinking and simulation to advance patient-centered prediction and decision support for complex chronic diseases. His work focuses on understanding how complex diseases evolve over time, why patients with similar diagnoses can follow different clinical trajectories, and how longitudinal clinical data can be translated into meaningful analytical frameworks. This perspective is grounded in the belief that chronic illness unfolds over time through the interaction of biology, treatment, behavior, and health system factors. By combining clinical insight with quantitative and computational modeling, his work aims to move beyond static risk prediction toward forecasting, simulation, and decision-support tools that better reflect the dynamic nature of chronic disease progression.
Why BioTraject exists
Healthcare increasingly has access to laboratory results, vital signs, medication histories, diagnoses, procedures, hospitalizations, and clinical notes. Much of that information remains fragmented across visits, care teams, and systems. BioTraject was created to help transform evolving clinical information into structured insight about patient state, trajectory, uncertainty, and possible future paths.
The current focus is chronic kidney disease through NephroSync™. Expansion beyond CKD will be deliberate, with each future application requiring its own knowledge, data, grounding, evaluation, validation, safeguards, and clearly defined intended use.
Mission and vision
Our mission is to build patient-specific computational decision systems that help clinicians and health organizations understand chronic disease trajectories, compare clinically bounded scenarios, and make better-timed decisions with appropriate confidence safeguards.
Our vision is to create the computational infrastructure through which longitudinal disease information can be organized, modeled, forecast, explained, and translated into structured clinical and scientific support.
Building a more dynamic future for chronic disease care.
BioTraject Systems is developing computational decision systems that transform longitudinal clinical information into a clearer understanding of disease trajectory, uncertainty, and possible future paths.
Long-term vision: to build the computational operating system for chronic disease care.
- Longitudinal measurements and how they change over time
- Treatment timing, sequencing, and response
- Acute events and instability
- Comorbidity and competing risks
- Individual heterogeneity across patients
BioTraject is built around the idea that these features should be represented explicitly — as an evolving, patient-specific trajectory rather than a static snapshot.
How we choose to build
BioTraject is guided by a set of foundational principles:
- Clinical usefulness — technology should answer meaningful clinical questions, not merely generate complex outputs.
- Patient-specific reasoning — population evidence matters, but individual trajectories and responses may differ.
- Longitudinal understanding — the meaning of a value depends on pattern, timing, context, and what came before it.
- Transparency and confidence — important assumptions, uncertainty, limitations, and use boundaries should remain visible.
- Validation and collaboration — capabilities should be evaluated before scale and developed with clinicians, researchers, health systems, and partners.
Collaboration and partnership
Important healthcare technology cannot be built in isolation. BioTraject welcomes conversations with clinicians, health systems, academic investigators, research networks, data and technology organizations, life-sciences companies, clinical informaticians, advisors, and strategic collaborators — across validation, pilots, workflow design, data integration, real-world evidence, implementation planning, product strategy, and responsible commercialization.
